merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>It offers an FDA‐approved, better-regulated alternative that addresses safety concerns associated with compounded drugs.</answer>
<question_number>2</question_number>
<answer>By selling directly through LillyDirect—providing transparent pricing and bypassing third-party telehealth services—Lilly challenges the compounded medication model.</answer>
<question_number>3</question_number>
<answer>Lower regulatory oversight that raises safety, quality, and effectiveness issues.</answer>
<question_number>4</question_number>
<answer>It aims to recapture market share by offering a lower-cost, regulated option that appeals to price-sensitive patients even if it shifts customers from its own pens.</answer>
<question_number>5</question_number>
<answer>Once tirzepatide is removed from the FDA shortage list, compounding pharmacies lose their regulatory exception, strengthening Lilly’s legal position.</answer>
<question_number>6</question_number>
<answer>It mirrors a direct-to-consumer strategy that eliminates intermediaries and provides transparent pricing.</answer>
<question_number>7</question_number>
<answer>Medicare beneficiaries may turn to the vials out-of-pocket due to noncoverage, potentially exposing them to safety risks.</answer>
<question_number>8</question_number>
<answer>It implies that the FDA-approved vials will be seen as a safer alternative to the unregulated compounded tirzepatide.</answer>
<question_number>9</question_number>
<answer>It is designated as being in shortage by the FDA.</answer>
<question_number>10</question_number>
<answer>Lowering its pricing to signal reclaiming market share from compounding pharmacies.</answer>